Inmunotek Australia

Inmunotek is a global pharmaceutical company focused on the development, manufacture, and commercialization of innovative solutions for allergy and immunology. The company specializes in allergen immunotherapy and bacterial vaccines designed to treat respiratory, dermatological, and infectious diseases. Their product portfolio includes Oraltek, a sublingual spray for respiratory allergies, and Uromune, a mucosal vaccine for recurrent urinary tract infections. Inmunotek Australia serves as the regional hub for providing these specialized immunological treatments to the Australian and New Zealand markets. The company maintains a strong emphasis on R&D, operating its own state-of-the-art manufacturing facilities to produce high-quality biologics and personalized medicines.